ICCC Q4 2023 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+30.3% YoY

Gross Profit

$1M24.7% margin

Operating Income

-$1M-19.7% margin

Net Income

-$1M-22.4% margin

EPS (Diluted)

$-0.15

QoQ Revenue Growth

-5.6%

Cash Flow

Operating Cash Flow

-$723,071

Free Cash Flow

-$804,415

Stock-Based Comp.

$100,659

Balance Sheet

Total Assets

$44M

Total Liabilities

$19M

Stockholders' Equity

$25M

Cash & Equivalents

$978,741

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$4M	+30.3%
Gross Profit	$1M	$2M	-20.4%
Operating Income	-$1M	-$2M	+38.6%
Net Income	-$1M	-$2M	+31.6%

Geographic Segments

UNITED STATES

$11M100%